March 2024

Silvercrest Asset Management Group Inc. (Silvercrest) has recently released its 2023 financial statements, providing investors and stakeholders with a comprehensive overview of the company's financial health and performance over the past year. This blog post aims to dissect the financial statemen...

Investing in publicly traded companies requires a thorough analysis of their financial health, market position, and future growth potential. One of the most critical tools for investors to evaluate these aspects is the company's 10-K filing with the Securities and Exchange Commission (SEC). This ...

In the ever-evolving landscape of the financial sector, FirstSun Capital Bancorp has emerged as a significant player. The company's 2023 10-K filing provides a wealth of information that sheds light on its operational strategies, financial health, and future prospects. This blog post aims to diss...

In the dynamic world of investments, the ability to accurately assess the potential of a publicly traded company is invaluable. This guide aims to demystify the process of evaluating a company's 10-K filing, focusing on key areas that signal its investment potential. By the end of this article, y...

NACCO Industries, Inc. (NACCO) has had a year of mixed results, as detailed in their 2023 annual report. The company, known for its operations in the natural resources sector, particularly in coal mining, North American mining, and minerals management, has faced challenges but also shows signs of...

PepGen Inc., a clinical-stage biotechnology company, has recently made its 10-K filing available, offering a detailed look into its operations, financial health, and future prospects. This review aims to dissect the 10-K filing, focusing on the company's business model, financial performance, and...

In the ever-evolving landscape of media and journalism, DallasNews Corporation stands as a beacon of quality journalism and innovative digital marketing solutions. The company's 2023 Annual Report provides a detailed insight into its operations, financial health, and strategic direction. This blo...

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company transitioning to a commercial-stage cell therapy entity, has made significant strides in the development of T-cell therapies for solid tumors. With the anticipation of its first marketing approval in 2024, the company is at ...

Investing in publicly traded companies requires a thorough analysis of various factors that can influence the company's future performance and, consequently, the return on investment. One of the most critical documents in this analysis is the company's 10-K filing with the Securities and Exchange...